BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38547242)

  • 1. MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription.
    Liu Z; Zhang X; Xu M; Hong JJ; Ciardiello A; Lei H; Shern JF; Thiele CJ
    PLoS Biol; 2024 Mar; 22(3):e3002240. PubMed ID: 38547242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN driven oncogenesis involves cooperation with WDR5 to activate canonical MYC targets and G9a to repress differentiation genes.
    Liu Z; Zhang X; Xu M; Hong JJ; Ciardiello A; Lei H; Shern JF; Thiele CJ
    bioRxiv; 2023 Jul; ():. PubMed ID: 37781575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
    Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T
    Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN.
    Yang R; Liu N; Li T; Liu F; Zhang J; Zhao H; Zou L; He X
    J Transl Med; 2023 Sep; 21(1):659. PubMed ID: 37741985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
    Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.
    Zeid R; Lawlor MA; Poon E; Reyes JM; Fulciniti M; Lopez MA; Scott TG; Nabet B; Erb MA; Winter GE; Jacobson Z; Polaski DR; Karlin KL; Hirsch RA; Munshi NP; Westbrook TF; Chesler L; Lin CY; Bradner JE
    Nat Genet; 2018 Apr; 50(4):515-523. PubMed ID: 29379199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.
    Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
    Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
    Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.
    Tu WB; Shiah YJ; Lourenco C; Mullen PJ; Dingar D; Redel C; Tamachi A; Ba-Alawi W; Aman A; Al-Awar R; Cescon DW; Haibe-Kains B; Arrowsmith CH; Raught B; Boutros PC; Penn LZ
    Cancer Cell; 2018 Oct; 34(4):579-595.e8. PubMed ID: 30300580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
    Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
    J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
    Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
    Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.
    Amente S; Milazzo G; Sorrentino MC; Ambrosio S; Di Palo G; Lania L; Perini G; Majello B
    Oncotarget; 2015 Jun; 6(16):14572-83. PubMed ID: 26062444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.
    Salib A; Jayatilleke N; Seneviratne JA; Mayoh C; De Preter K; Speleman F; Cheung BB; Carter DR; Marshall GM
    Oncogene; 2024 Jan; 43(5):363-377. PubMed ID: 38049564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.
    Horvilleur E; Bauer M; Goldschneider D; Mergui X; de la Motte A; Bénard J; Douc-Rasy S; Cappellen D
    Nucleic Acids Res; 2008 Aug; 36(13):4222-32. PubMed ID: 18583365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
    Armstrong MB; Mody RJ; Ellis DC; Hill AB; Erichsen DA; Wechsler DS
    Neoplasia; 2013 Dec; 15(12):1363-70. PubMed ID: 24403858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.
    Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z
    Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
    Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
    Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.
    Hu X; Liu R; Hou J; Peng W; Wan S; Xu M; Li Y; Zhang G; Zhai X; Liang P; Cui H
    Oncogene; 2022 Sep; 41(37):4295-4306. PubMed ID: 35978151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.